Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and β-cell dysfunction. Among available oral antidiabetic agents, only the thiazolidinediones (TZDs) primarily target insulin resistance. TZDs improve insulin sensitivity by activating peroxisome proliferator-activated receptor γ...

Full description

Bibliographic Details
Main Authors:	Jaehyun Bae, Taegyun Park, Hyeyoung Kim, Minyoung Lee, Bong-Soo Cha
Format:	Article
Language:	English
Published:	Korean Diabetes Association 2021-05-01
Series:	Diabetes & Metabolism Journal
Subjects:	diabetes mellitus, type 2 lobeglitazone thiazolidinediones
Online Access:	http://e-dmj.org/upload/pdf/dmj-2020-0272.pdf

Similar Items

Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks
by: Soo Lim, et al.
Published: (2017-10-01)

Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice
by: Kyoung Min Kim, et al.
Published: (2017-09-01)

The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition
by: Yu Seol Lee, et al.
Published: (2018-09-01)

Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis
by: Yang Liu, et al.
Published: (2018-01-01)

Thiazolidinedione and cardiovascular risk in type 2 diabetes mellitus
by: Yenny Yenny
Published: (2016-04-01)

The Effect of Diabetes Mellitus, Insulin, and Thiazolidinediones on Bone Histomorphometry in Streptozotocin-induced Diabetic Postmenopausal Wistar Rats
by: Derya Köseoğlu, et al.
Published: (2021-03-01)

Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice
by: Kwi-Hyun Bae, et al.
Published: (2017-02-01)

Lobeglitazone Attenuates Airway Inflammation and Mucus Hypersecretion in a Murine Model of Ovalbumin-Induced Asthma
by: Na-Rae Shin, et al.
Published: (2018-08-01)

Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
by: Eugene Han, et al.
Published: (2018-07-01)

Appropriateness of the use of Thiazolidinediones for the treatment of Type 2 Diabetes Mellitus at the Southern Arizona Veterans Affairs Hospital
by: Fletcher, Glory, et al.
Published: (2005)

The Effects of Pioglitazone on Respiratory Function Test in Patients with Asthma and Type 2 Diabetes Mellitus- A before –after Study
by: Reyhaneh Azizi, et al.
Published: (2019-12-01)

Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis
by: Zhiwei Zhang, et al.
Published: (2017-04-01)

The effect of metformin and thiazolidinedione use on lung cancer in diabetics
by: Mazzone Peter J, et al.
Published: (2012-09-01)

Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones
by: Kyeong Won Lee, et al.
Published: (2011-08-01)

Evaluation of the efficiency and safety of therapy with a combination of sulfonylurea derivatives and insulin sensitizers for type 2 diabetes mellitus
by: O N Goncharenko, et al.
Published: (2012-08-01)

Patient factors associated with hemoglobin A1C change with pioglitazone as adjunctive therapy in type 2 Diabetes Mellitus
by: Tran MT, et al.
Published: (2008-06-01)

Evaluation of the impact of cardiovascular safety concerns of thiazolidinediones on the utilization of oral antidiabetic drugs
by: Bui, Cat Nguyen
Published: (2011)

No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects
by: Kim YK, et al.
Published: (2021-04-01)

Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke
by: Chang Ho Ahn, et al.
Published: (2019-05-01)

The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety
by: Charles E. Leonard, et al.
Published: (2020-02-01)

The role of pharmacogenetics in the treatment of diabetes mellitus
by: Topić Elizabeta
Published: (2014-01-01)

Challenges in drug discovery for thiazolidinedione substitute
by: Jian-ping Ye
Published: (2011-10-01)

Antimicrobial screening of new 5-(chromene-3-yl) methylene-2,4-thiazolidinediones
by: Cristina Nastasă, et al.
Published: (2015-08-01)

Effect of hyperglycemia and thiazolidinediones on cardiac angiotensin converting enzyme 2 (ACE2) and neprilysin (NEP) in db/db diabetic mice.
by: Fadnavis, Rucha
Published: (2017)

Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerbations in new-onset COPD patients with advanced diabetic mellitus: a cohort-based case–control study
by: Kuan-Yuan Chen, et al.
Published: (2021-04-01)

Biological potential of thiazolidinedione derivatives of synthetic origin
by: Sucheta, et al.
Published: (2017-12-01)

A New Symmetrical Thiazolidinedione Derivative: In Silico Design, Synthesis, and In Vivo Evaluation on a Streptozotocin-Induced Rat Model of Diabetes
by: Samuel Álvarez-Almazán, et al.
Published: (2021-07-01)

Effect of oral hypoglycaemic agents on bone metabolism in patients with type 2 diabetes mellitus & occurrence of osteoporosis
by: B Siddhartha Kumar, et al.
Published: (2015-01-01)

The inhibition of adenylate kinase by 2,4-thiazolidinedione evaluated by protein-ligand docking
by: Mihaela Ileana Ionescu
Published: (2017-03-01)

Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel
by: Sanjay Kalra, et al.
Published: (2020-01-01)

Comparison of the Effects of Various Antidiabetic Medication on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
by: Jeonghoon Ha, et al.
Published: (2021-08-01)

Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study
by: Nam Hoon Kim, et al.
Published: (2017-06-01)

Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health?
by: Ki Dong Ko, et al.
Published: (2017-06-01)

A Pharmacovigilance Approach for Assessing Cardiovascular, Osteological, and Carcinogenic Risk Associated with Thiazolidinedione Drugs Used in the Treatment of Type 2 Diabetes Mellitus
by: Davidson, Melissa Anne
Published: (2018)

A new series of 2,4-thiazolidinediones endowed with potent aldose reductase inhibitory activity
by: Sever Belgin, et al.
Published: (2021-03-01)

Risk of fracture with thiazolidinediones: an individual patient data meta-analysis
by: Marloes T Bazelier, et al.
Published: (2013-02-01)

MYOCARDIAL FIBROSIS IN PATIENTS WITH DIABETES MELLITUS
by: O. M. Drapkina, et al.
Published: (2015-09-01)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
by: Schwartz S
Published: (2010-07-01)

Noninsulin pharmacological management of type 1 diabetes mellitus
by: Vishvas Garg
Published: (2011-01-01)

Pioglitazone Improves Survival In Patients With Cancer: The Hypothesis
by: Banshi Saboo, et al.
Published: (2015-12-01)